Investors focused on the Medical space have likely heard of Inogen (INGN Quick QuoteINGN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Inogen is a member of the Medical sector. This group includes 818 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. INGN is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for INGN's full-year earnings has moved 16.93% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, INGN has gained about 93.91% so far this year. Meanwhile, the Medical sector has returned an average of 11.58% on a year-to-date basis. This means that Inogen is performing better than its sector in terms of year-to-date returns.

Looking more specifically, INGN belongs to the Medical - Instruments industry, which includes 92 individual stocks and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have gained about 27.81% so far this year, so INGN is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to INGN as it looks to continue its solid performance.